We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome (T-OPTIMUM)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01763580
First Posted: January 9, 2013
Last Update Posted: September 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Korea, Inc. )
  Purpose
To compare the therapeutic effect of tacrolimus in combination with low-dose corticosteroid with high-dose corticosteroid alone in patients with minimal-change nephrotic syndrome.

Condition Intervention Phase
MCNS Minimal Change Nephrotic Syndrome (MCNS) Drug: Tacrolimus Drug: Prednisolone Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS)

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc ( Astellas Pharma Korea, Inc. ):

Primary Outcome Measures:
  • The percentage of subjects who show a decreased UPCR (Urine Protein Creatinine Rate) of less than 0.2 [ Time Frame: up to 8 weeks after treatment ]

Secondary Outcome Measures:
  • The period until the UPCR is decreased below 0.2 [ Time Frame: up to 8 weeks after treatment ]
  • The percentage of subjects who show relapse after the remission [ Time Frame: up to 24 weeks ]
  • The period until the relapse happens from the complete remission [ Time Frame: up to 24 weeks ]
  • Safety assessed by the incidence of adverse events, labo-tests, vital signs, ECGs and chest X-rays [ Time Frame: up to 24 weeks ]

Enrollment: 144
Actual Study Start Date: July 16, 2012
Study Completion Date: August 21, 2017
Primary Completion Date: May 2, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tacrolimus with low-dose corticosteroid
Oral
Drug: Tacrolimus
Oral
Other Names:
  • FK506
  • Prograf Capsule
Drug: Prednisolone
Oral
Active Comparator: High-dose corticosteroid alone
Oral
Drug: Prednisolone
Oral

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 78 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients who have been diagnosed with initial or relapsed primary minimal-change nephrotic syndrome
  • patients whose urine protein-creatinine ratio (UPCR) is more than 3.0

Exclusion Criteria:

  • patients whose eGFR is less than 30 ml/min/1.73 m2
  • patients who were treated with immunosuppressants, such as tacrolimus, cyclosporine, cyclophosphamide (Cytoxan), mizoribine (Bredinin), levamisole, azathioprine, mycophenolate mofetil, or rituximab, within two weeks before the study
  • patients to whom more than 10 mg prednisolone or an equivalent dose of steroid was administered daily within two weeks before the study
  • patients who are pregnant, breastfeeding, or planning to be pregnant or to breastfeed within six months after the study completion, or who cannot or do not want to use any contraceptive method
  • patients who are hypersensitive to the investigational drug or to macrolide, such as azithromycin, clarithromycin, or roxithromycin
  • patients who were treated with a live vaccine within four weeks before the study
  • patients whose liver panel laboratory test result is three times the normal range, or acute hepatitis patients whose serum bilirubin has been clinically significantly higher than 3.6 mg/dL for more than 1 month
  • patients who have a significant general disease that makes it inappropriate for them to participate in this study as adjudged by the investigator (e.g., cardiovascular-acute myocardial infarction, heart failure [classified as more than New York Heart Association {NYHA} class III], hepatic/gastrointestinal/neurologic disease, blood disorder, cancer, infection, renal disorder other than minimal-change nephrotic syndrome, rheumatic arthritis with pneumonia interstitials)
  • patients who have genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
  • patients to whom another investigational drug was administered within 30 days from the enrollment in the study
  • patients who participated in the past phases of this study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763580


Locations
Korea, Republic of
Seoul, Korea, Republic of
Sponsors and Collaborators
Astellas Pharma Korea, Inc.
Investigators
Study Director: Medical Director Astellas Pharma Inc
  More Information

Responsible Party: Astellas Pharma Korea, Inc.
ClinicalTrials.gov Identifier: NCT01763580     History of Changes
Other Study ID Numbers: PRGNS-11-02-KOR
First Submitted: December 6, 2012
First Posted: January 9, 2013
Last Update Posted: September 14, 2017
Last Verified: September 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Korea, Inc. ):
Glomerulonephritis
Tacrolimus
Nephrotic syndrome

Additional relevant MeSH terms:
Syndrome
Nephrotic Syndrome
Nephrosis
Nephrosis, Lipoid
Disease
Pathologic Processes
Kidney Diseases
Urologic Diseases
Tacrolimus
Prednisolone
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents